Bioventus Inc. (NYSE:BVS) CFO Sells $113,018.49 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 10,733 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $10.53, for a total value of $113,018.49. Following the transaction, the chief financial officer now directly owns 105,162 shares in the company, valued at approximately $1,107,355.86. This trade represents a 9.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bioventus Stock Performance

Shares of NYSE BVS traded up $0.32 during trading hours on Thursday, reaching $11.00. 255,781 shares of the stock were exchanged, compared to its average volume of 391,340. The firm has a market capitalization of $892.71 million, a price-to-earnings ratio of -18.03 and a beta of 0.79. The stock’s fifty day simple moving average is $11.89 and its 200 day simple moving average is $9.76. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38.

Bioventus (NYSE:BVS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $138.96 million for the quarter, compared to analysts’ expectations of $132.57 million. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. During the same quarter last year, the business earned $0.05 EPS. Sell-side analysts predict that Bioventus Inc. will post 0.41 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BVS. Canaccord Genuity Group boosted their target price on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Craig Hallum lifted their price objective on shares of Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, September 27th. Finally, JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and increased their price objective for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th.

Institutional Trading of Bioventus

A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new stake in shares of Bioventus during the 2nd quarter worth $647,000. HB Wealth Management LLC bought a new position in Bioventus in the 2nd quarter valued at about $60,000. Panagora Asset Management Inc. bought a new stake in shares of Bioventus during the 2nd quarter worth approximately $787,000. Rhumbline Advisers increased its stake in Bioventus by 5,367.9% in the second quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock valued at $302,000 after acquiring an additional 51,478 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Bioventus by 403.1% during the second quarter. Acadian Asset Management LLC now owns 27,956 shares of the company’s stock valued at $159,000 after purchasing an additional 22,399 shares in the last quarter. Institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.